Chu, Zhaowei
Gu, Lei
Hu, Yeguang
Zhang, Xiaoyang http://orcid.org/0000-0002-0031-0290
Li, Man
Chen, Jiajia http://orcid.org/0000-0002-5378-6284
Teng, Da
Huang, Man http://orcid.org/0000-0002-9806-0794
Shen, Che-Hung
Cai, Li
Yoshida, Toshimi http://orcid.org/0000-0001-7080-6913
Qi, Yifeng http://orcid.org/0000-0002-1511-5818
Niu, Zhixin
Feng, Austin
Geng, Songmei
Frederick, Dennie T. http://orcid.org/0000-0003-3355-5267
Specht, Emma
Piris, Adriano
Sullivan, Ryan J. http://orcid.org/0000-0001-5344-6645
Flaherty, Keith T. http://orcid.org/0000-0002-3402-0478
Boland, Genevieve M.
Georgopoulos, Katia http://orcid.org/0000-0002-8963-4258
Liu, David
Shi, Yang http://orcid.org/0000-0001-9713-1709
Zheng, Bin http://orcid.org/0000-0002-0998-7177
Funding for this research was provided by:
This work is supported by the Melanoma Research Alliance, Sun Pharma-SID Mid-Career Investigator Award and funds from MGH
Article History
Received: 19 November 2020
Accepted: 22 March 2022
First Online: 6 April 2022
Competing interests
: Y.S. is a co-founder and equity holder of Constellation Pharmaceuticals and Athelas Therapeutics, a consultant for Active Motif, and an equity holder of Imago Biosciences. K.T.F has served on the Board of Directors of Clovis Oncology, Strata Oncology, Loxo Oncology, and Checkmate Pharmaceuticals; Scientific Advisory Boards of X4 Pharmaceuticals, PIC Therapeutics, Sanofi, Amgen, Asana, Adaptimmune, Fount, Aeglea, Shattuck Labs, Tolero, Apricity, Oncoceutics, Fog Pharma, Neon, Tvardi, xCures, Monopteros, and Vibliome; consultant to Lilly, Novartis, Genentech, BMS, Merck, Takeda, Verastem, Boston Biomedical, Pierre Fabre, and Debiopharm; and research funding from Novartis and Sanofi. G.M.B has sponsored research agreements with Olink Proteomics, Palleon Therapeutics, InterVenn Biosciences, and Takeda Oncology; served on scientific advisory boards for Novartis, Merck, Nektar Therapeutics, Iovance, and Ankyra Therapeutics; consultant to InterVenn Biosciences, Ankyra Therapeutics, and Merck. The remaining authors declare no competing interests.